# Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

> **NCT01175473** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 148 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Lixisenatide (AVE0010)
- **DEVICE:** Pen auto-injector
- **DRUG:** Liraglutide
- **DEVICE:** Pre-filled pen injector
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01175473
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175473, "Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01175473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*